Treatment of Acute Leukemia Relapse After Allotransplantation
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Patients with relapse of acute leukemia often only receive supportive therapy. Our hypothesis
is that a combination therapy can stabilize the disease for patients with early relapse after
allogeneic stem cell transplantation. The investigators will combine 5-azacitidine 100 mg
daily subcutaneously (days 1-3), valproic acid (continuous therapy from day 1), All-trans
retinoic acid (days 1-14) and hydroxurea (continuous treatment from day 15 of first cycle.
Azacitidine and ATRA can be repeated with 5 weeks intervals, donor leukocyte infusions on day
10 is allowed from the second cycle.